TPI Initiates the Official Relocation Process to Qionglai Tianyin Facility (QLF)

CHENGDU, China, Jan. 12, 2015 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced the official start of the relocation procedure from the Company's original Longquan Facility to its Qionglai Tianyin Facility (QLF), expecting the imminent Good Manufacturing Practice (GMP) certification following TPI's completion of Public Notice (Gong Shi) Status for its QLF from the China Food & Drug Administration (CFDA) (http://www.scfda.gov.cn/directory/web/WS19/CL2076/96334.html). The pictures of the QLF can be viewed on the front page of Company's website: www.tianyinpharma.com

About QLF Relocation Project

In preparation for the new GMP standards stipulated by the government of China in early 2011, TPI initiated the process of optimizing the manufacturing facilities in compliance with the new GMP standards. Due to the redesigning of the industrial parks in the suburbs of Chengdu, TPI's manufacturing facility at the Longquan district, east of Chengdu, is scheduled to be relocated to Qionglai city, south of Chengdu, which is designated for pharmaceutical industry. The QLF, occupying 80 mu or over 13 acres, is approximately 18 miles from the Company's recently completed Jiangchuan macrolide (JCM) facility. The designed production capacity of QLF is 30% higher than the TPI's currently operating Longquan facility. The QLF is a combination of both pre-extraction plant and formulation plant. The pre-extraction facility is designated for processing and purifying raw materials for TCMs using ethanol or distilled water precipitation, filtration, centrifugation, concentration and purification. The TCM extracts will then be processed for the production of mTCM products at the formulation facility where the final biopharmaceutical, TCM and generic products in the forms of oral liquid, granules, tablets, and capsules are produced. In September 2014, the Company has successfully completed the site visit for GMP certification, during which a team of GMP experts and specialists along with CFDA officials conduct a thorough examination of production facility in terms of pre-extraction process, formulation process and various aspects of the pharmaceutical manufacturing procedure. TPI is expecting to receive GMP certificate for its QLF within this week.

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 10 are included in the essential drug list of China. For more information about TPI, please visit:  http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com, or email: [email protected]

Tel: +86-28-8551-6696 (Chengdu, China)
Address:
Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza     
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China

SOURCE Tianyin Pharmaceutical Co., Inc.

Related Links

http://www.tianyinpharma.com